Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 11:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 84 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Androgel (testosterone gel) Clear all
Not listed Phase 1Phase 2 Interventional

TRT in Combination With Electrical Stimulation and Standing: Effect on Muscle and Bone in Spinal Cord Injured Males

NCT02317640
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Testosterone Gel applied by a pump, Stand Training, Electrical Stimulation
Drug · Other · Device
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 58 Years · Male only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 2, 2026, 11:43 AM EDT
Completed Phase 2 Interventional Results available

Normalization of Morning Testosterone Levels in Men With Secondary Hypogonadism

NCT01270841
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Placebo, topical testosterone, Androxal
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
21 Years to 65 Years · Male only
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
18
States / cities
Garden Grove, California • Sacramento, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2014 · Synced Oct 2, 2026, 11:43 AM EDT
Completed Phase 4 Interventional Results available

The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel

NCT01893281
View directory record Official record
Conditions
Hypogonadism
Interventions
Topical Testosterone Solution
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
21
States / cities
Encinitas, California • San Diego, California • Parker, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2014 · Synced Oct 2, 2026, 11:43 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

HOP-3 Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone

NCT00839319
View directory record Official record
Conditions
Healthy Males
Interventions
Acyline, placebo hCG (no active ingredient), hCG (human chorionic gonadotropin), Testosterone gel
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 11, 2016 · Synced Oct 2, 2026, 11:43 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

TEAM: Testosterone Supplementation and Exercise in Elderly Men

NCT00112151
View directory record Official record
Conditions
Healthy
Interventions
LowT, Resistance Training, Placebo, HighT
Drug · Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
60 Years and older · Male only
Enrollment
167 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Oct 2, 2026, 11:43 AM EDT
Withdrawn Phase 4 Interventional

Testosterone and Pain Sensitivity

NCT01689896
View directory record Official record
Conditions
Low Testosterone, Hypogonadism, Pain
Interventions
Testosterone Gel, Placebo Gel
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Oct 2, 2026, 11:43 AM EDT
Completed Phase 2 Interventional

A One Year Open Label Study for the Treatment of Hypogonadism (Low Testosterone) in Men Who Have Completed ZA-203

NCT01386567
View directory record Official record
Conditions
Hypogonadism, Low Testosterone
Interventions
Androxal (enclomiphene citrate), Testim (topical testosterone)
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
21 Years to 65 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
8
States / cities
Garden Grove, California • Sacramento, California • San Diego, California + 2 more
Source: ClinicalTrials.gov public record
Updated May 17, 2013 · Synced Oct 2, 2026, 11:43 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

TRADE-Testosterone Replacement and Dutasteride Effectiveness

NCT00194675
View directory record Official record
Conditions
Hypogonadism, Benign Prostatic Hyperplasia
Interventions
Dutasteride, Testosterone gel, Placebo dutasteride
Drug
Lead sponsor
University of Washington
Other
Eligibility
50 Years and older · Male only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Oct 2, 2026, 11:43 AM EDT
Recruiting Phase 4 Interventional

Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance

NCT06733350
View directory record Official record
Conditions
Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions
Biopsy of Prostate, Biospecimen Collection, Magnetic Resonance Imaging, Patient Observation, Questionnaire Administration, Therapeutic Testosterone
Procedure · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 2, 2026, 11:43 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

PROS-1-Male Hormonal Contraceptive Regimens on Prostate Tissue

NCT00490555
View directory record Official record
Conditions
Healthy
Interventions
Testosterone gel, Dutasteride, Depo-Medroxyprogesterone (DMPA), Placebo Testosterone gel, Placebo dutasteride, Placebo DMPA
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
25 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 15, 2013 · Synced Oct 2, 2026, 11:43 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

The Testosterone Trials in Older Men

NCT00799617
View directory record Official record
Conditions
Andropause
Interventions
AndroGel® (testosterone gel), Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
65 Years and older · Male only
Enrollment
790 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2018
U.S. locations
12
States / cities
Birmingham, Alabama • La Jolla, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 2, 2026, 11:43 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes

NCT02513940
View directory record Official record
Conditions
Long QT Syndrome
Interventions
Testosterone, Progesterone, Placebo, Ibutilide
Drug
Lead sponsor
Indiana University
Other
Eligibility
65 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 2, 2026, 11:43 AM EDT
Terminated Early Phase 1 Interventional Results available

Testosterone for Penile Rehabilitation After Radical Prostatectomy

NCT00848497
View directory record Official record
Conditions
Hypogonadism, Erectile Dysfunction
Interventions
Testim®, Placebo Testim®, Viagra®
Drug · Other
Lead sponsor
Mohit Khera
Other
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 19, 2015 · Synced Oct 2, 2026, 11:43 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Androgel in the Treatment of Hypogonadal and Low Testosterone Men With Type 2 Diabetes

NCT00141492
View directory record Official record
Conditions
Type 2 Diabetes, Hypogonadism
Interventions
Androgel (testosterone gel)
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
30 Years to 80 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
70
States / cities
Birmingham, Alabama • Calera, Alabama • Mobile, Alabama + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2015 · Synced Oct 2, 2026, 11:43 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Testosterone and Alendronate in Hypogonadal Men

NCT01460654
View directory record Official record
Conditions
Hypogonadism, Osteopenia, Osteoporosis
Interventions
Testosterone, Alendronate, Placebo Alendronate, Placebo Testosterone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years to 85 Years · Male only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 2, 2026, 11:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of Testosterone on Prostate Tissue (ACYP-1)

NCT00161486
View directory record Official record
Conditions
Hypogonadism, Contraception
Interventions
Testosterone gel, Acyline, Placebo acyline, Placebo Testosterone gel
Drug
Lead sponsor
University of Washington
Other
Eligibility
35 Years to 55 Years · Male only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 19, 2008 · Synced Oct 2, 2026, 11:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

NES Gel-1, To Evaluate Nestorone Gel in Combination With Testosterone Gel

NCT00229593
View directory record Official record
Conditions
Contraception
Interventions
Nestorone gel, Testosterone Gel
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
2
States / cities
Torrance, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Oct 2, 2026, 11:43 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism

NCT00467987
View directory record Official record
Conditions
Type 2 Diabetic Male With Hypogonadotrophic Hypogonadism
Interventions
androgel, placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
31 Years to 60 Years · Male only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Oct 2, 2026, 11:43 AM EDT
Completed Phase 3 Interventional

Bioequivalence Study of Test and Reference Testosterone Topical Gel, 1.62% Metered Pump in Testosterone Deficient Adult Male Subjects Under Fasting Conditions

NCT02110368
View directory record Official record
Conditions
Primary Hypogonadism, Hypogonadotropic Hypogonadism
Interventions
Testosterone Topical Gel, 1.62% Metered Pump, AndroGel (testosterone gel) 1.62% Metered-Dose Pump
Drug
Lead sponsor
Amneal Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Miami Gardens, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Oct 2, 2026, 11:43 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Regulation of Cortisol Metabolism and Fat Patterning

NCT00694733
View directory record Official record
Conditions
Obesity, Menopausal Syndrome
Interventions
Placebo injection, Depo Lupron/Aromatase inhibitor, Depo Lupron/placebo, placebo, Estrogen cream
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 62 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 16, 2022 · Synced Oct 2, 2026, 11:43 AM EDT
Completed Phase 3 Interventional

Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)

NCT01235754
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
transdermal testosterone gel 1%, placebo gel
Drug
Lead sponsor
BioSante Pharmaceuticals
Industry
Eligibility
30 Years to 66 Years · Female only
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
98
States / cities
Hoover, Alabama • Huntsville, Alabama • Mobile, Alabama + 91 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 2, 2026, 11:43 AM EDT
Completed Phase 4 Interventional

Natesto Spermatogenesis Reboot

NCT05381831
View directory record Official record
Conditions
Hypogonadism, Male
Interventions
NatestoTM
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 64 Years · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 2, 2026, 11:43 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women

NCT00657501
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
testosterone gel, placebo gel
Drug
Lead sponsor
BioSante Pharmaceuticals
Industry
Eligibility
30 Years to 65 Years · Female only
Enrollment
575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
66
States / cities
Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 2, 2026, 11:43 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

ITT4 Intratesticular Hormonal Milieu in Man (ITT4)

NCT01215292
View directory record Official record
Conditions
Healthy Males
Interventions
Acyline, Testosterone gel, ketoconazole 400, Ketoconazole 800, Dutasteride, Anastrozole, Placebo ketoconazole
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Oct 2, 2026, 11:43 AM EDT